OXGENE, a WuXi Advanced Therapies (WuXi ATU) company, based in Oxford, UK, provides cell and gene therapy pioneers around the world with the technologies, automation platforms and service solutions they need to come first in the race to deliver ground-breaking therapeutics. OXGENE™ is headquartered in Oxford, UK. For additional information, please visit our website.
| Website | https://www.oxgene.com |
| Revenue | $17.6 million |
| Employees | 101 (1 on RocketReach) |
| Founded | 2011 |
| Technologies |
JavaScript
,
HTML
,
Twitter
+17 more
(view full list)
|
| Industry | Biotechnology Research, Biotechnology |
| Keywords | Gene Therapy, Cell Therapy, Gene Editing, Viral Vectors, Cell Line Engineering, Crispr Technology, Bioprocessing, Cell Culture, Recombinant Proteins, Process Development, Upstream Processing, Downstream Processing, Biotechnology, Scale Up, Drug Development, Pharmaceutical Manufacturing, Life Sciences, Manufacturing |
| Competitors | Thermo Fisher Scientific, AstraZeneca, Moderna Therapeutics, Intellia Therapeutics, Inc., CRISPR Therapeutics, bluebird bio, Editas Medicine, Sangamo Therapeutics, Inc., Cellectis, Uncork Capital +45 more (view full list) |
Looking for a particular OXGENE employee's phone or email?
The OXGENE annual revenue was $17.6 million in 2026.
Jocelyne Bath is the Managing Director of OXGENE.
1 people are employed at OXGENE.